All In Biotech

Drug Trial Radar · NCT01307397

A Study of Vemurafenib in Participants With Metastatic Melanoma

An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma

Last checked: Nov 20, 2026Latest source record: Dec 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,219

Actual

Start

Mar 1, 2011

Primary completion

Feb 24, 2016

Study completion Feb 24, 2016

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer \[AJCC\]) metastatic melanoma.

Conditions

  • Malignant Melanoma

Interventions

  • VemurafenibDrug

    Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0Time frame: Baseline up to 28 days post end of treatment (maximum up to 46 months)
  2. Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug DiscontinuationTime frame: Baseline up to 28 days post end of treatment (maximum up to 46 months)
  3. Percentage of Participants With AEs of Special InterestTime frame: Baseline up to 28 days post end of treatment (maximum up to 46 months)
  4. Mean Cumulative Dose of VemurafenibTime frame: Baseline up to end of treatment or death (maximum up to 46 months)
  5. Duration of Vemurafenib TreatmentTime frame: Baseline up to end of treatment or death (maximum upto 46 months)
  6. Mean Total Vemurafenib Dose Per DayTime frame: Baseline up to end of treatment or death (maximum up to 46 months)
  7. Dose Intensity of VemurafenibTime frame: Baseline up to end of treatment or death (maximum upto 46 months)

Locations

280 sites in 44 countries. Site status is shown where the registry gives one.

  • University "Mother Theresa" Hospital Center; Oncology Department

    Tirana, Albania

  • Hospital Britanico; Oncologia

    Buenos Aires, Argentina

  • Fundación CIDEA

    Buenos Aires, Argentina

  • Inst. Alexander Fleming; Oncologia

    Buenos Aires, Argentina

  • Melanoma Institute Australia

    North Sydney, New South Wales, Australia

  • Newcastle Mater Misericordiae Hospital; Oncology

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Border Medical Oncology

    Wodonga, New South Wales, Australia

  • Greenslopes Private Hospital; Gallipoli Research Centre

    Greenslopes, Queensland, Australia

  • The Townsville Hospital; Townsville Cancer Centre

    Townsville, Queensland, Australia

  • Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital; Oncology

    Adelaide, South Australia, Australia

  • Geelong Hospital; Geelong Cardiology Practice

    Geelong, Victoria, Australia

  • Peter MacCallum Cancer Centre; Medical Oncology

    Melbourne, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin

    Feldkirch, Austria

  • LKH Graz; Abteilung für allgemeine Dermatologie

    Graz, Austria

  • LKH Innsbruck; Universitätsklinik für Dermatologie

    Innsbruck, Austria

  • Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie

    Linz, Austria

  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

    Salzburg, Austria

  • LKH Salzburg; Universitätsklinik für Dermatologie

    Salzburg, Austria

  • Landesklinikum St. Pölten

    Sankt Pölten, Austria

  • Medizinische Universität Wien; Univ.Klinik für Dermatologie

    Vienna, Austria

  • UZ Brussel

    Brussels, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Sint Augustinus Wilrijk

    Wilrijk, Belgium

  • University Clinical Center of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • Clinic of Oncology, University Clinical Center Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • Instituto Nacional de Cancer - INCa; Pesquisa Clinica

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Hospital A. C. Camargo; Oncologia

    São Paulo, São Paulo, Brazil

  • Hospital Sao Jose

    São Paulo, São Paulo, Brazil

  • District Oncology Dispensary; Department for Oncology and Dermatology

    Plovdiv, Bulgaria

  • National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic

    Sofia, Bulgaria

  • Cross Cancer Institute ; Dept of Medical Oncology

    Edmonton, Alberta, Canada

  • Lion'S Gate Hospital

    North Vancouver, British Columbia, Canada

  • British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • St. Boniface General Hospital; Medicine

    Winnipeg, Manitoba, Canada

Showing 40 of 280 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.